


### **MEDICINAL PRODUCTS 2020**

## MYRIAD GENETICS INC Rank 11 of 52









#### **MEDICINAL PRODUCTS 2020**

# Myriad genetics

#### MYRIAD GENETICS INC Rank 11 of 52

The relative strengths and weaknesses of MYRIAD GENETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MYRIAD GENETICS INC compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 57% points. The greatest weakness of MYRIAD GENETICS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 91%, being 96% points above the market average of -4.3%.

Input Variable	Value in 1000 USD
Assets, Current	348,600
Assets, Non-Current	54,900
General and Administrative Expense	555,500
Goodwill	1,101,900
Liabilities, Current	117,800
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-1,100
Other Expenses	197,700
Other Liabilities	356,000
Other Net Income	-7,600
Other Revenues	851,100
Property, Plant and Equipment, Net	57,300
Research and Development	85,900

Output Variable	Value in 1000 USD
Liabilities	473,800
Assets	1,562,700
Expenses	839,100
Revenues	851,100
Stockholders Equity	1,088,900
Net Income	4,400
Comprehensive Net Income	3,850
Economic Capital Ratio	91%

